Trial reportScientific reports2026
Ranolazine as an adjunct to standard therapy for angina in myocardial bridging: a randomized clinical trial.
Trial report in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myocardial bridging (MB) is a common anatomical variation in which myocardial fibers traverse over an epicardial coronary artery, potentially leading to angina or angina- equivalent symptoms. Ranolazine, known for its efficacy in chronic stable angina, might offer benefits in symptomatic MB, where traditional treatments often fall short. This prospective, parallel-group, double-blind, randomized add-on clinical trial was conducted at Al-Zahra Cardiovascular Teaching Hospital, Shiraz, Iran, from 2023 to 2024. We included patients with MB and angina symptoms who had normal epicardial coronary arteries. Participants were randomized into two groups: one receiving standard therapy (β-blockers) and the other receiving standard therapy plus ranolazine (500 mg twice daily). Outcomes were assessed using the Canadian Cardiovascular Society (CCS) classification of angina, echocardiographic left ventricular ejection fraction (LVEF), and electrocardiogram (ECG) parameters. Trial registry number: IRCT20230801059005N2 (08/11/2023). Among 52 participants, ranolazine addition significantly improved angina severity, with more patients transitioning to CCS grade I (p = 0.001 after adjusting for confounders). While univariate analysis showed no differences in ECG parameters, multivariate analysis revealed a modest but statistically significant QTc prolongation in the ranolazine group (OR = 1.055, 95%CI:1.012-1.100, p = 0.012). PR and QRS intervals remained unaffected. Post-treatment LVEF was comparable between the two groups. Ranolazine, as an adjunct to β-blockers, significantly improved angina symptoms in patients with myocardial bridging and was associated with a mild but significant QTc prolongation, without causing substantial changes in LVEF or other ECG parameters. These findings suggest that ranolazine could be a beneficial addition to the management of angina in MB patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.